Anzeige
Mehr »
Login
Donnerstag, 12.09.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Beispiellose Goldfunde: Deshalb achten Investoren auf dieses Unternehmen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
389 Leser
Artikel bewerten:
(2)

Velico Medical, Inc: The American National Red Cross Teams Up With Velico Medical In The Blood Center Education Program

BOSTON, Feb. 6, 2024 /PRNewswire/ -- Velico Medical is proud to announce the company's collaboration with the American National Red Cross in its technology development initiative, the Blood Center Education Program (BCEP).

Velico's BCEP is designed to provide strategic blood center partners the opportunity to get hands-on experience with its FrontlineODP system for spray drying plasma, evaluate potential integration into blood component production operations and provide critical feedback on the commissioning and operational aspects of the system.

"This collaboration reflects the shared vision of Velico and the Red Cross of advancing life-saving blood products with the goal of improving patient care in the United States and around the world," says Richard Meehan, President, and CEO of Velico.

"The Red Cross has built a time-honoured legacy of leadership, innovation and an unwavering commitment to patients as reflected in its mission of ensuring that everyone in our country has access to safe, lifesaving blood and blood products," says Pampee P. Young, M.D., Ph.D., Chief Medical Officer Biomedical Services with the Red Cross.

FrontlineODP is expected to be an easy to produce, easy to use, point-of-care dried plasma product for transfusion in settings where current plasma products (most often frozen) are unavailable or inconvenient to use because of challenging cold chain logistics and short dating. With FrontlineODP, plasma could become more readily available to first responders such as ground or air ambulances, in rural hospitals where plasma is typically not stocked, for the military, and during mass casualty events.

"The Red Cross is committed to advancing novel blood and plasma products which are designed to extend care to the point of injury," says Tim Washburn, Vice President, Product Strategy & Management with the Red Cross. "The collaboration will create the foundation for advancing dry plasma research opportunities between our organizations," adds Bethany L Brown, PhD, MSCS, Senior Director, Transfusion Innovation and Product Development with the Red Cross.

Velico's development program has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00059.

About Velico:
Velico Medical, Inc. is a private US medical technology company, committed to the mission of eliminating preventable death from bleeding. Headquartered in Beverly, Massachusetts, USA. Velico personnel have substantial expertise and experience in transfusion medicine and medical device development. In support of its mission, Velico is developing partnerships with civilian, government and military blood center leadership, trauma surgeons, emergency medical physicians, military medics and first responders worldwide.

About the American Red Cross:

The American Red Cross shelters, feeds and provides comfort to victims of disasters; supplies about 40% of the nation's blood; teaches skills that save lives; distributes international humanitarian aid; and supports veterans, military members and their families. The Red Cross is a nonprofit organization that depends on volunteers and the generosity of the American public to deliver its mission. For more information, please visit redcross.org or cruzrojaamericana.org, or visit us on Twitter at @RedCross.

Pictured (L-R) are Bethany L Brown, PhD, MSCS, Senior Director, Transfusion Innovation and Product Development, American Red Cross, Richard Meehan, President & Chief Executive Officer, Velic,Pampee P. Young, M.D., Ph.D., Chief Medical Officer, Biomedical Services, American Red Cross, Bill Skillman, Senior Vice President,Velico and Tim Washburn, Vice President, Product Strategy & Management, American Red Cross.


Video - https://mma.prnewswire.com/media/2334425/American_Red_Cross_collaborates_with_Velico.mp4
Photo - https://mma.prnewswire.com/media/2334424/Velico_Red_Cross_SIgning.jpg
Logo - https://mma.prnewswire.com/media/2152986/4530752/Velico_Medical_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/the-american-national-red-cross-teams-up-with-velico-medical-in-the-blood-center-education-program-302054468.html

© 2024 PR Newswire
Drei potenzielle Vervielfacher aus Osteuropa

In unserem kostenlosen Spezialreport nehmen wir Sie mit auf eine Reise durch die dynamischen und oft unterbewerteten Aktienmärkte Osteuropas. Die Region erlebt ein beeindruckendes Wirtschaftswachstum, das weit über den Erwartungen vieler Analysten liegt. Während westliche Märkte gesättigt erscheinen, bieten osteuropäische Unternehmen einzigartige Investitionsmöglichkeiten zu attraktiven Bewertungen.

Profitieren Sie vom Wachstum Osteuropas!

In dieser Ausgabe stellen wir Ihnen drei Top-Aktien vor, die nicht nur durch solide Fundamentaldaten glänzen, sondern auch durch ein enormes Wachstumspotenzial in den kommenden Jahren. Erfahren Sie, warum diese Favoriten bereit sind, die Märkte zu erobern und wie Sie als Investor von dieser Entwicklung profitieren können.

Verpassen Sie nicht die Chance, Teil dieser aufstrebenden Wirtschaft zu sein. Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, bei welchen unentdeckten Perlen noch enormes Potenzial schlummert.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.